Partnership Formed to Explore Personalized Medicine Approach for Amyotrophic Lateral Sclerosis (ALS) Treatments
The partnership will integrate Denovo’s pharmacogenomic technology into the analysis of biological samples obtained from expanded access programs (EAP’s) that ALS-ETF sponsors. By identifying genomic biomarkers that correlate with patients’ responsiveness to treatment, the partners seek to identify appropriate patient subsets for the conduct of subsequent trials.
“This exciting relationship with Denovo Biomarkers may accelerate the development of drugs for ALS and may help us provide useful information for patients and physicians,” said
About The ALS Emergency Treatment Fund (ALS-ETF)
The ALS Emergency Treatment Fund, headquartered in
About Denovo Biomarkers
Denovo Biomarkers, based in
SOURCE The ALS Emergency Treatment Fund